Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: A unique cancer therapy

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Barliya, Tilda ^a   Mandel, Mathilda ^a   Livnat, Tami ^a   Weinberger, Dov ^b,c   Lavie, Gad ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; HEAT SHOCK PROTEIN 90; HYPERICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PROTEASOME; UBIQUITIN; VON HIPPEL LINDAU PROTEIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PERYLENE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CATABOLISM; CELL HYPOXIA; CELL LEVEL; CELL PH; CONTROLLED STUDY; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; KIDNEY CARCINOMA; LYSOSOME; OXYGEN CONCENTRATION; PIGMENT EPITHELIUM; POLYUBIQUITINATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN STABILITY; TUMOR VASCULARIZATION; UBIQUITINATION; CELL LINE; DNA RESPONSIVE ELEMENT; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PH; PROMOTER REGION; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CATHEPSIN B; CELL HYPOXIA; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; METABOLISM; NEOPLASMS; PERYLENE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RESPONSE ELEMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UBIQUITINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80052900733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022849     Document Type: Article

References (44)

1. Huang LE, Arany Z, Livingston DM, Bunn HF, (1996) Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem 271: 32253-32259.
2. Minet E, Mottet D, Michel G, Roland I, Raes M, et al. (1999) Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 460: 251-256.
3. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, et al. (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62: 2478-2482.
4. Falkman J, (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
5. Ochel HJ, Schulte TW, Nguyen P, Trepel J, Neckers L, (1999) The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase. Mol Genet Metab 66: 24-30.
6. Messaoudi S, Peyrat JF, Brion JD, Alami M, (2008) Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem 8: 761-782.
7. Cortese JD, Schwab B 3rd, Frieden C, Elson EL, (1989) Actin polymerization induces a shape change in actin-containing vesicles. Proc Natl Acad Sci USA 86: 5773-5777.
8. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
9. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, et al. (2009) Glioma derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1a. Science 324: 261-265.
10. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, et al. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-a prolyl hydroxylase. Cancer Cell 7: 77-85.
11. Semenza GL, (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634.
12. Blank M, Lavie G, Mandel M, Hazan S, Orenstein A, et al. (2004) Antimetastatic activity of the photodynamic agent hypericin in the dark. Int J Cancer 111: 596-603.
13. Lavie G, Mandel M, Hazan S, Barliya T, Blank M, et al. (2005) Anti angiogenic activities of hypericin in vivo: potential for ophthalmologic applications. Angiogenesis 8: 35-42.
14. Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G, (2003) Enhanced ubiquitinylation of Hsp90 as a potential mechanism of mitotic cell death in cancer cells induced with hypericin. Cancer Res 63: 8241-8247.
15. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, et al. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1a-degradative pathway. J Biol Chem 277: 29936-29944.
16. Koga F, Tsutsumi S, Neckers LM, (2007) Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle 6: 1393-1402.
17. Giaccia AJ, Simon MC, Johnson R, (2004) The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev 18: 2183-2194.
18. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, et al. (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741.
19. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, et al. (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427.
20. Sureau F, Miskovsky P, Chinsky L, Turpin PY, (1996) Hypericin-induced cell photosensitization involves an intracellular pH decrease. J Am Chem Soc 118: 9484-9487.
21. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, et al. (2007) HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12: 230-238.
22. Quintero M, Brennan PA, Thomas GJ, Moncada S, (2006) Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1α in cancer: role of free radical formation. Cancer Res 66: 770-774.
23. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL, (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004.
24. Masson-Gadais B, Houle F, Laferriere J, Huot J, (2003) Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones 8: 37-52.
25. Matsumoto T, Claesson-Welsh L, (2001) VEGF receptor signal transduction. Sci STKE 112: RE21.
26. Kubis HP, Hanke N, Scheibe RJ, Gros G, (2005) Accumulation and nuclear import of HIF1 alpha during high and low oxygen concentration in skeletal muscle cells in primary culture. Biochim Biophys Acta 1745: 187-195.
27. Hur E, Kim HH, Choi SM, Kim JH, YIM S, et al. (2002) Reduction of Hypoxia-Induced Transcription through the Repression of Hypoxia-Inducible Factor-1α/Aryl Hydrocarbon Receptor Nuclear Translocator DNA Binding by the 90-kDa Heat-Shock Protein Inhibitor Radicicol. Mol Pharmacol 62: 975-982.
28. Chen S, Smith DF, (1998) Hop as an adaptor in the heat shock protein 70 (Hsp70) and Hsp90 chaperone machinery. J Biol Chem 273: 35194-35200.
29. Kubota H, Yamamoto S, Itoh E, Abe Y, Nakamura A, et al. (2010) Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinoma. Cell Stress Chaperones 15: 1003-1011.
30. Blank M, Mandel M, Hazan S, Keisari Y, Lavie G, (2001) Anti-cancer activities of hypericin in the dark. Photochem Photobiol 74: 120-125.
31. Aoyagi S, Archer TK, (2005) Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 15: 565-567.
32. Bali F, Pranpat M, Bradner J, Balasis M, Fiskus W, et al. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for anti leukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729-26734.
33. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, et al. (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601-607.
34. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, (2007) RACK1 competes with HSP90 for binding to HIF-1a and is required for O2-independent and HSP90 inhibitor-induced degradation of HIF-1α. Mol Cell 25: 207-217.
35. Semenza GL, (2000) HIF-1 and human disease: one highly involved factor. Genes Dev 14: 1983-1991.
36. Redepenning J, Tao N, (1993) Measurement of formal potentials for hypericin in dimethyl sulfoxide. Photochem Photobiol 58: 532-535.
37. Gerson F, Gescheidt G, Haering P, Mazur Y, Freeman D, et al. (1995) Electron acceptor properties of hypericin and its salts: an ESR/ENDOR and electrochemical study. J Am Chem Soc 117: 11861-11866.
38. Kong X, Lin Z, Liang D, Fath D, Sang N, (2006) Histone deacetylase inhibitors induce VHL and ubiquitin independent proteasomal degradation of hypoxia-inducible factor 1α. Mol Cell Biol 26: 2019-2028.
39. Yang K, Cepko CL, (1996) Flk-1, a receptor for vascular endothelial growth factor (VEGF), is expressed by retinal progenitor cells. J Neurosci 16: 6089-6099.
40. Thomas JA, Buchsbaum RN, Zimniak A, Racker E, (1979) Intracellular pH measurements in Ehrlich ascites tumor cells utilizing spectroscopic probes generated in situ. Biochemistry 18: 2210-2218.
41. Zoratti M, Favaron M, Pietrobon D, Petronilli V, (1984) Nigericin-induced transient changes in rat-liver mitochondria. Biochim Biophys Acta 767: 231-239.
42. Ho AK, O'Brien L, Girard M, Chik CL, (1992) Intracellular pH on protein kinase C and ionomycin potentiation of isoproterenol-stimulated cyclic AMP and cyclic GMP production in rat pinealocytes. J Neurochem 59: 2304-2310.
43. Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, et al. (2007) Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 67: 3239-3253.
44. Couldwell WT, Surnock AA, Tobia AJ, Cabana BE, Stillerman CB, et al. (2011) A Phase I/II Study of Orally Administered Synthetic Hypericin for Treatment of Recurrent Malignant Gliomas. Cancer doi:10.1002/cncr.26123.